<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1107">
  <stage>Registered</stage>
  <submitdate>22/03/2006</submitdate>
  <approvaldate>22/03/2006</approvaldate>
  <nctid>NCT00306540</nctid>
  <trial_identification>
    <studytitle>Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder</studytitle>
    <scientifictitle>A Multicentre, Parallel Group, Randomised, Double Blind, Placebo Controlled Study of the Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>D1449L00005</secondaryid>
    <secondaryid>AU-SEA-0006</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Post-Traumatic Stress Disorder</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Anxiety</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Depression</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Quetiapine Fumarate
Treatment: drugs - quetiapine fumarate placebo

Active Comparator: 1 - Placebo Seroquel + existing therapy

Experimental: 2 - Seroquel + existing therapy


Treatment: drugs: Quetiapine Fumarate
oral flexible dose

Treatment: drugs: quetiapine fumarate placebo
oral 0 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Administered PTSD Scale (CAPS2)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Depression Scale (HAM-D)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hamilton Anxiety Scale (HAM-A)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Posttraumatic Stress Disorder Checklist (PCL)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impressions (CGI)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Hospitalised and non-hospitalised patients / Veteran or Civilian / Have had symptoms
             of PTSD for a minimum of 12 months prior to giving consent to the study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of psychotic condition / quetiapine or other anti-psychotics not worked
             previously / Taking prohibited medications (mood stabilizers / substance abuse)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>90</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2008</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,SA,VIC</recruitmentstate>
    <hospital>Research Site - Brisbane</hospital>
    <hospital>Research Site - Adelaide</hospital>
    <hospital>Research Site - Melbourne</hospital>
    <postcode> - Brisbane</postcode>
    <postcode> - Adelaide</postcode>
    <postcode> - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AstraZeneca</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate how effective quetiapine versus placebo is when
      added to an existing therapy, in reducing the symptoms of PTSD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00306540</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>AstraZeneca Australia Medical Director, MD</name>
      <address>AstraZeneca</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>